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Life expectancy after the diagnosis and treatment of
cancer has increased significantly in the past two decades,
and therefore more patients survive either cancer-free
or with cancer as a chronic, manageable disease.1,2
Unfortunately, many anticancer drugs have been
associated with the development of cardiovascular
complications such as left ventricular dysfunction and
heart failure, myocardial, cerebral and peripheral ischae-
mia, pericarditis and myocarditis, hypertension, throm-
boembolism, QTc prolongation and arrhythmias.3,4 Each
of these is likely to have significant effects on patient
outcomes. Therefore, a new discipline, that is ‘cardio-
oncology’, was born in an effort to study, prevent,
recognize and treat the cardiovascular sequelae of anti-
tumour drugs.5 As anticancer drugs save lives, the logical
goal of cardio-oncology, besides preventing or mitigating
cardiotoxicity (CTX), is to promote an acceptable balancebetween the potential cardiovascular side effects and
the vital benefit of anticancer treatment.6
This document has been prepared with the main
objective of promoting cooperation between the oncol-
ogist and the cardiologist and to support the growth of
cardio-oncology among cardiologists. It is specifically
addressed to the cardiologist who is asked to make
strategic decisions in the management of cancer patients,
but has not accumulated enough experience in the field
of cardio-oncology.
This opinion paper and the others in this issue do not
address the wide spectrum of cardiovascular compli-
cations of cancer therapy, but rather, they discuss left
ventricular dysfunction, focusing on possible strategies to
prevent or manage the CTX of the three major classes of
drugs: anthracyclines (ANTs), anti-Her-2 and tyrosine
kinase inhibitor. Not all treatments affect the heart the
same way. In fact, there are important differencesDOI:10.2459/JCM.0000000000000381
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time of onset of CTX.7 Furthermore, CTX may occur
in many clinical settings which differ in type, stage,
clinical presentation and prognosis of cancer and with
regard to the presence of other concomitant medication-
related types of cardiac and noncardiac toxicity. It is
therefore impossible to provide general recommen-
dations on how to manage patients being treated with
these drugs: each group would require specific measures
and a separate discussion.
Anthracycline cardiotoxicity: mechanisms and
pathophysiology
We have known about the cardiotoxic effects of ANT,
since they started being used. Depending on when
cardiac abnormalities appear, ANT-induced CTX
(A-CTX) was initially classified as acute, subacute or
chronic.8 It was soon understood that both acute and
subacute toxicity are of limited clinical relevance,
whereas chronic CTX, which may arise several months
after completion of treatment in the form of congestive
heart failure, was identified as the most common form
of damage caused by ANT and the most important
in clinical practice.9 It was then acknowledged that
the incidence of chronic A-CTX strongly depends on
the cumulative dose of the drug and increases with older
age, systemic hypertension or preexisting cardiovascular
disease (CVD) and mediastinal irradiation.9,10
Further studies found that both covert left ventricular
dysfunction and heart failure may occur in patients trea-
ted with ANT after an asymptomatic period lasting
longer than 1 year. This event was defined as late
A-CTX.11,12
The most accredited interpretation of A-CTX implies
the increase, through the formation of iron-complexes,
of reactive oxygen species, which results in mitochondrial
dysfunction, changes in calcium homeostasis and
contractile function, and loss of cardiomyocytes by
apoptosis.13–16
Recently, it was suggested that topoisomerase 2b is
the key mediator of A-CTX, whose inhibition causes
double-strand breaks in DNA, defective mitochondrial
biogenesis and increased reactive oxygen species,
resulting in cardiomyocyte death.17
A unifying hypothesis that could explain the adverse
cardiovascular events in chronic and late forms is that
A-CTX is both dose and time dependent. At high doses,
ANT induces cardiomyocyte death and dysfunction,
which both lead to hypokinetic cardiomyopathy within
months. At low doses, they seem to inhibit the progenitor
cell-mediated self-healing potential of the heart.18,19 The
consequences may become clinically relevant many years
later, when the effects of ageing and many other types of
stress, including hypertension, diabetes and cardiac
ischaemia are not counterbalanced by the renewal of© 2016 Italian Federation of Ccardiomyocytes by the paracrine repairing mechanisms
of progenitor cells. This hypothesis fits well, and offers a
mechanistic explanation to the ‘multiple-stress’ hypoth-
esis that was proposed a few years ago, which states that
patients treated with ANT have increased susceptibility
to cardiac stress which would otherwise be harmless for
untreated peers.20,21
As of their CTX, ANTs are currently used much less
frequently. Nevertheless, they are still the backbone of
the treatment of many solid and haematological tumours,
including breast and gastric cancer, sarcoma, leukaemia
and lymphoma.The need for, and purpose of, a cardiology
consultation
A number of excellent reviews, editorials and practical
recommendations on how to manage patients treated
with potentially cardiotoxic drugs emphasize the import-
ance of the cardiological evaluation of patients before and
during cancer therapy. Moreover, several practical algor-
ithms, including ECG, dosage of biomarkers and echo-
cardiography have been proposed.22–24 Although they do
not specify whether all patients receiving anticancer
therapy should be referred for a cardiology consultation,
and in fact, the tendency is to request a consult only for
patients with known CVD, high-risk profile, or abnorm-
alities of laboratory parameters, including biomarkers,
left ventricular ejection fraction (LVEF) and global longi-
tudinal strain (GLS) analysis.24
On the other hand, authoritative experts believe that it is
up to the cardiologist to perform the baseline cardiology
evaluation in all patients, and have a dialogue with the
oncologist practicing treatment in patients who are con-
sidered at intermediate or high risk for CTX, in an
attempt to balance oncologic benefit with the cardiovas-
cular risk prevention.23
It is important to bear in mind that in the past few years
it has become very clear that(1) tardhere are no low-risk patients. The AHA/ACC
Guidelines for the Diagnosis and Management of
heart failure in Adults state that all patients treated
with potentially cardiotoxic drugs are Class A heart
failure patients25;(2) unexpected cardiac complications, be they docu-
mented or even suspected, that occur during cancer
treatment can have a major impact on the viability of
therapies26;(3) late CTX is a matter of growing concern for patients
treated with potentially cardiotoxic drugs11,12,27;(4) the decision to adopt prophylactic treatment with
cardioprotective agents can be substantially effective
in several patients28–30; and(5) appropriate modification of cardiovascular risk factors
can provide significant benefits towards limiting theiology. All rights reserved.
e86 Journal of Cardiovascular Medicine 2016, Vol 17 (suppl 1)unwanted cardiovascular effects of cancer and its
treatment.31Therefore, even if we do not have guidelines, we suggest
carrying out a cardiology consultation for all candidates to
ANT treatment.
We see an analogy between the cardiology evaluation
before anticancer therapy and the evaluation which
precedes noncardiac surgery in moderate-to-high
cardiovascular risk patients. The ACC/AHA Guidelines
on Perioperative Cardiovascular Evaluation and Care for
Noncardiac Surgery state that ‘the purpose of preopera-
tive evaluation is not simply to givemedical clearance but
rather to perform an evaluation of the patient’s current
medical status; make recommendations concerning the
evaluation, management, and risk of cardiac problems
over the entire perioperative period; and provide a
clinical risk profile that the patient, primary physician,
anaesthesiologist, and surgeon can use in making treat-
ment decisions that may influence short- and long-term
cardiac outcomes’.32 This statement is very well suited
for patients who are candidates for anticancer therapy.
Mutatis mutandis, the oncologist should inform the cardi-
ologist about the malignancy and the proposed therapy.
The cardiologist should not simply approve or deny the
proposed treatment, but he/she should consider the over-
all cardiac risk, suggest how to prevent CTX and then
inform the patients, their relatives and the primary phys-
icians about the possible long-term cardiac outcomes.
Baseline cardiology consultation: general
approach
The baseline cardiology consultation should be modu-
lated according to the nature of the oncological illness. It
is the duty of the oncologist to ensure that the salient
information about the overall plan of patient care and
prognosis, as well as the clinical circumstances and
comorbidities are incorporated into the cardiology assess-
ment. The oncologist should also inform the cardiologist
about the risk of noncardiac toxicity, including anaemia,
neutropenia or renal toxicity, that could have a strong
impact on cardiac patients. All the patient’s data, includ-
ing any previous cardiology records, should be available
for the cardiologist to review.
The cardiologist has to obtain the patient’s medical
history, and should perform a physical examination
including a detailed cardiovascular study, supplemented
by an ECG and an echocardiogram. Measurement of
troponin and BNP should also be carried out.22,24,33,34
Echocardiography is the method of choice for evaluating
cardiac risk in patients receiving anticancer therapy as it
allows a comprehensive evaluation of the cardiac struc-
ture and function.24 It includes, but is not limited to, the
measurement of LVEF. It is important to emphasize that
LVEF is not the only parameter that must be taken into
consideration. Indeed, the oncologist should be informed© 2016 Italian Federation of Cathat this isolated evaluation may be misleading if
other echocardiographic parameters, such as myocardial
hypertrophy, diastolic function and valvular functions are
not critically taken into due consideration. Evaluation of
the GLS may contribute to risk stratification, as patients
with GLS below the lower limit of normal are at
intermediate or high risk, even if LVEF is normal.24
Evidence-based scoring systems to calculate cardiac risk
in the context of anticancer therapy are not yet available.
Therefore, the cardiologist must refer to the traditional
cardiovascular risk factors while keeping in mind that
people with hypertension, advanced age or any docu-
mented CVD are at increased risk for CTX. If the base-
line findings are indicative of severe impairment or active
CVD, patients are to be considered at high CTX risk.23
It is the responsibility of the cardiologist to ensure clear
communication with patients, who must be as well
informed of their cardiac conditions as possible. An
intervention aimed at behavioural changes to
prevent or correct all cardiovascular risk factors has to
be initiated. Hypertension, diabetes and dyslipidaemia
have to be aggressively treated. When necessary, beta-
blockers and renin-angiotensin-aldosterone system
(RAAS) antagonists should be part of treatment.35
Furthermore, the threshold for deciding whether to
add statins should be low.35 Lastly, a frank conversation
should be reserved to patients at high or intermediate
oncological risk so that they may accept the optimal
anticancer treatment without excessive concern for
CTX. Strategies for switching to less cardiotoxic regimes
in the presence of unacceptable cardiac risk should be
discussed with the patient’s oncologist.
Cardiology management, before and during
anthracycline therapy
The algorithm for the management of CTX in patients
receiving ANTs is shown in Fig. 1. Before starting
treatment with ANTs, the cardiologist should stratify
the risk, taking into account the four main factors that
influence CTX onset: cumulative doses of ANT9; old age
or preexisting heart diseases9,23; favourable cancer
prognosis with expected long survival (e.g. breast cancer
at an early stage and lymphomas) which increases the risk
of late CTX1,27; exposure to further treatment after the
end of ANT therapy, as in the case of HER-2þ breast
cancer patients designated to receive trastuzumab or
similar target therapies. ANT activates the stress path-
ways of cardiomyocytes, as well as the survival pathways,
the most important of which is the neuregulin/HER-2
system. By inhibiting the HER-2 receptor, Trastuzumab
impairs this survival pathway and creates an imbalance in
favour of the toxic effects of ANTs.36,37 Accordingly,
clinical studies showed that the incidence and severity
of anti-HER-2-induced myocardial dysfunction signifi-
cantly increases in women pretreated with ANT.38rdiology. All rights reserved.
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Fig. 1
Baseline evaluation
Cardiologist’s consult, ECG, ECHO, troponin
Cardiotoxicity risk assessment
- Cardiac risk profile (aging, risk factors, heart diseases)
- Good oncological prognosis (→ late toxicity)
- Anthracycline doses
- Anti-HER2 scheduled therapy
Optimize current therapy  
- Switch antihypertensive therapy
  to ACE-I or new generation BB
- treat all cardiac risk factors
Patient education 
- Recognition of symptoms
- Prevention and treatment of
  all cardiac risk factors
Consider
cardioprotective strategies
- Dexrazoxane
- Liposomal anthracyclines
- Cardiac drugs
Consider
non-containg anthracycline CT
Dialogue with
oncologist/hematologist Low risk High risk
START  anthracycline-CT
End of anthracycline-ct evaluation
ECG, ECHO, troponin
Optional in low risk pts
Tn at each cycle
Suggested in high risk pts
Optional in low risk pts
Echo at middle therapy
(If more than 4 cycles)
Suggested in high risk pts
NEG
POS
ECHO
NEG
POS
Tn - Cardiological consultation
- Start cardiac therapy
- Cardiological consultation
- Start cardiac therapy
- Consider to hold
   anthracycline therapy
NEG
POS
ECHO
NEG
POS
ECHO at 6 months
- Cardiological consultation
- Start cardiac therapy
NEG Yearly clinical evaluation; consider ECHO
Algorithm for the management of cardiotoxicity in patients receiving anthracyclines. BB, beta-blockers; CT, chemotherapy; ECHO, echocardiograms;
Tn, Troponin.In addition, patients should be informed about the risk
of cardiac events, particularly with regard to the late form
of CTX. On the other hand, they must fully understand
the role of the cardiologist, who is responsible for pro-
tecting cardiac function, but whose aim is also to prevent
premature discontinuation of therapy. Patients should
be aware of the need for repeated medical testing, as
the effects of ANTs may appear many years later when
the cancer follow-up could be tapered or suspended
altogether.
Although the optimal surveillance for patients treated
with ANTs is not standardized, it is advisable to repeat
echocardiography at the end of ANT therapy in all
patients. For patients who are going to receive more than
four cycles of chemotherapy—especially those deemed
to be at high risk at baseline—an interim analysis must be
foreseen after the third cycle. A drop in LVEF of more© 2016 Italian Federation of Cthan 10% compared with baseline, to a value less than
53% during ANT-based chemotherapy, or immediately
after its completion, is a rare, but potentially serious
event. In these cases, it is essential to assess troponin
and BNP, to reassess LVEF after 2 weeks and to request a
cardiology consultation in view of starting cardiac
therapy. If the decline in LVEF occurs before the end
of chemotherapy, the alternative options of discontinuing
chemotherapy, switching to a less cardiotoxic regimen, or
adapting the ANT therapy, should be discussed with the
oncologist as soon as possible.
Cardiac MRI, a noninvasive technique that does not
involve exposure to ionizing radiation, has emerged as
a sensitive and reproducible alternative to echocardio-
graphy for the evaluation of the cardiac structure and
function during cancer therapy.39,40 As cardiac MRI is not
easily accessible and is costly, the current suggestion is toardiology. All rights reserved.
e88 Journal of Cardiovascular Medicine 2016, Vol 17 (suppl 1)consider cardiac MRI for patients for whom echocardio-
graphy is not technically feasible or optimal, or when
highly accurate assessment of LVEF is crucial for asses-
sing possible chemotherapy discontinuation.
Primary prevention
Primary prevention is aimed at avoiding CTX from
the very beginning of ANT administration. Although a
number of strategies have been proposed, coadministra-
tion of dexrazoxane or the use of liposomal preparations
has proven to be the most feasible approaches. A third
possibility, which is pretreatment with beta-blockers and
RAAS antagonists, albeit promising, has limited favour-
able evidence.
Dexrazoxane
Dexrazoxane is a neutral prodrug that is infused within
30min prior to ANT administration. It spreads easily in
the cardiomyocytes where, upon hydrolytic metabolism,
it exerts its twomost important cardioprotective activities
which are preventing iron-based oxidative stress and
inhibiting topoisomerase 2b.41,42
Dexrazoxane is the only U.S. Food and Drug Adminis-
tration approved cardioprotective agent. Cardioprotec-
tion by dexrazoxane has been consistently documented
in many clinical studies that investigated its efficacy, in
both children and adults.28,43–45 Dexrazoxane is therefore
a reliable and effective means for preventing A-CTX.46
Nonetheless, dexrazoxane is only prescribed in a small
percentage of patients treated with ANT, and there is
considerable discrepancy among oncologists regarding its
use.47,48 This is because of the unjustified concern that
dexrazoxane may interfere with the antitumour activity
of ANTs and that it might increase the risk of secondary
tumours.49,50 A number of studies have conclusively
refuted this unfounded belief,51,52 which, however, had
a negative impact on the decisions of regulatory agencies
and some restrictions on its use.
The opinion of the working group of the International
Colloquium on Cardio-oncology, a forum that brings
together many of the leading experts in cardioncology,
must be cited, and in our opinion shared. They recently
expressed the view that dexrazoxane should be re-
assessed for broader clinical use.6
Liposomal anthracyclines
Liposomal ANTs are boundwithin artificial phospholipid
membrane vesicles that are used as drug carriers.53 Large,
randomized controlled trials and meta-analyses on
metastatic breast cancer patients showed that liposomal
formulations significantly reduce the CTX risk that is
observed with conventional ANTs, without affecting
antitumour activity.29,54–56 The low propensity of
liposomal ANTs to cause CTX is well documented by
studies evaluating the efficacy and safety of these drugs
when administered in selected patients at very high risk© 2016 Italian Federation of Caof CTX because of advanced age, frailty, ANT pretreat-
ment, preexisting CVD or concomitant trastuzumab
treatment.57–60
Reduced CTX of liposomal ANTs should be ascribed
to their different biodistribution and pharmacokinetics.
Liposomes accumulate in the tumour tissue because of
increased intratumour capillary permeability and
decreased lymphatic clearance from perivascular space.53
On the contrary, uptake of the drug by the myocardium is
diminished because the heart is supplied by vessels with
tight junctions and the interstitial spaces are well drained
by lymphatic vessels. Pegylated liposomal doxorubicin is
a class of liposomal drug systems referred to as Stealth
liposomes. It is known that the rate at which the lipo-
some-encapsulated drug can be cleared from the systemic
circulation is influenced by the uptake and destruction of
circulating liposomes by the reticuloendothelial system.
Because of the polyethylene-glycol grafting on the
liposome bilayer, pegylated liposomal doxorubicin has
lower uptake by the reticuloendothelial system, resulting
in a unique pharmacokinetic model characterized by
extremely long half-life, slow clearance and small volume
of distribution.53 Thus, it is believed that in adult patients
at high risk of CTX, the liposomal formulation is a
feasible option and, in many cases, the only possibility
for performing the ANT-based therapy.
Dexrazoxane and liposomal ANT reduce, but do not
eliminate CTX risk. The decision on whether or not to
monitor patients during chemotherapy depends greatly
on the clinical circumstances. Low-risk patients under-
going primary prevention mainly to limit late CTX do
not require monitoring during therapy. Vice versa, high-
risk patients, and particularly those in whom the use of
primary prevention is deemed to be the only way to
receive ANT must be monitored during treatment.
Beta-blockers, RAAS antagonists, statins
This paragraph weighs the pros and cons of using
these drugs in cancer patients who are ‘healthy’ from a
cardiovascular point of view. At the moment, there are no
large randomized, prospective trials that clearly show the
benefits of this form of primary prevention.
On the other hand, recent studies on small groups of
patients report promising results with the use of third
generation beta-blockers (carvedilol or nebivolol) or
RAAS antagonists.30,61–66 Cancer and anticancer therapy,
however, is associated with fatigue and a variety of
haemodynamic modifications such as hyper- or hypoten-
sion, hyper- or hypovolemia, and changes in sympathetic
or parasympathetic tone, which can fluctuate greatly
during treatment. Therefore, the use of vasoactive drugs
may cause or exacerbate the distressing and debilitating
symptoms, including dizziness, hypotension, and fatigue.
Thus, caution is recommended before starting therapy
for primary prevention with beta-blockers or RAASrdiology. All rights reserved.
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cotreatment with these drugs, it becomes mandatory to
start with very low doses, to closely monitor heart rate,
blood pressure and kidney function, and should symp-
toms appear, to reevaluate patients as quickly as possible.
Retrospective studies document that among patients
treated with ANT-based chemotherapy, those who had
already received statins to prevent CVD experienced less
deterioration in LVEF.68 This finding, together with the
lack of adverse haemodynamic effects and the powerful
antioxidant and anti-inflammatory ability of statins,
suggest a potentially protective effect of these com-
pounds against A-CTX.69 There is currently not enough
evidence to warrant recommending statin administration
to the general population of patients scheduled for
ANT therapy.
Secondary prevention
Secondary prevention aims to prevent left ventricular
dysfunction in patients with very early signs of
A-CTX. This strategy is based on the following elements:
the relatively short duration of therapy—4–6 cycles of
drugs administered over 4–6 months—suggests that the
optimal strategy for monitoring patients must be planned;
a decrease in LVEF is an event that occurs rather late
during ANT therapy and therefore, repeated measure-
ment is not a highly sensitive tool for detecting early
CTX; an early increase in plasma troponin or decrease in
left ventricular systolic deformation indexes, in particular
GLS, precedes changes in LVEF and are more sensitive
and specific for detecting early CTX70–73; identification
of these ‘primordial’ CTX signs suggests an increased
cardiac risk, which, however, does not exceed the
advantage of maintaining ANT therapy; and in selected
patients, treatment with drugs for heart failure may be
cardioprotective if administered under the cardiologist’s
supervision.74,75
Limited scientific data prevent solid recommendations
on secondary prevention from being made, although
the following information may be helpful to cardiologists
in order to determine how to implement the standard
management of patients by using secondary prevention
measures.
Longitudinal strain
GLS is the most accurate echocardiographic index for
detecting subtle changes in myocardial function and it is
able to predict the development of ANT-induced cardio-
myopathy.72,73 As it is unthinkable to use this technique
before each chemotherapy cycle, GLS should be assessed
at every scheduled echocardiographic examination
(beginning and end of therapy and, where appropriate,
at mid-term). Evaluating changes in GLS is particularly
useful when LVEF decreases by less than 10% and drops
to a value less than 53%. In these cases, a relative
decrease in GLS more than 15% from baseline should© 2016 Italian Federation of Cbe considered a sign of CTX, thus requiring a cardiology
consultation in order to start cardiac therapy and to
determine whether or not to maintain or postpone
chemotherapy.24 A relative drop in GLS of 8–15% should
be evaluated case by case.
Troponin
A large body of clinical evidence proves that an increase
in troponin levels identifies ANT-induced cardiac injury
and allows early identification of patients at risk of left
ventricular dysfunction or heart failure.22,70,71 Moreover,
because of its high negative predictive value, troponin
identifies patients at low risk of subsequently developing
ANT cardiomyopathy. There are also data from a single
centre, which show that patients with troponin elevation
greatly benefit from the use of angiotensin-converting
enzyme inhibitors.74,75 Despite these promising results,
many experts believe that the practical usefulness
of serial troponin assessment needs to be definitively
established. Many centres are reluctant to rely on tropo-
nin in their environment of clinical trials. Although tim-
ing of sample collection, cut-off values and comparability
between various troponin assays have yet to be resolved,
troponin has many of the prerequisites of a good bio-
marker: tests can be carried out in series with ease, are
easily available and inexpensive when compared with
imaging, and are already largely employed in many
pathological conditions.76 This latter point is important
because the more a test is used in current cardiology
evaluation, the better it can be used in the specific
context of ANT CTX. We suggest that troponin should
be measured at each cycle and even one month after the
end of CT. It was in fact shown that troponin positivity at
the end of chemotherapy is a rare event that however
indicates that the patient is at high risk of left ventricular
dysfunction or heart failure.71
If troponin is found to be above the cut-off point, it would
be appropriate to perform an echocardiogram, dose the
BNP, and start cardiac therapy, whereas the ANT
therapy should not be discontinued unless a significant
decrease in LVEF is observed.
Pharmacological treatment in secondary prevention
The effort to identify patients at risk of CTX would be in
vain, if there were no treatment options. Herein, doubts
have been expressed concerning the administration of
beta-blockers or RAAS antagonists in primary prevention;
on the contrary, the use of these drugs should be encour-
aged in secondary prevention, once patients have been
identified by troponin and/or strain evaluation as being at
higher risk of left ventricular dysfunction.22
We suggest that therapy with angiotensin-converting
enzyme inhibitors should be started first, quickly
followed by the addition of beta-blockers. With regard
to patient monitoring and dose titration, we refer our
readers to current treatment guidelines for heart failure.ardiology. All rights reserved.
e90 Journal of Cardiovascular Medicine 2016, Vol 17 (suppl 1)Although the undesirable effects of these drugs still
remain, therapeutic management should preferably be
supervised by the cardiologist who, moreover, should pay
close attention to ensure that cardiovascular treatments
do not endanger the chances of completing ANT therapy.
Cardiomyopathy surveillance for
anthracycline-exposed survivors
All patients treated with ANT and their healthcare
providers should be aware of the risk of developing
ANT-related cardiomyopathy. This event may occur
after a long latency period and asymptomatic left ven-
tricular dysfunction, with progressive signs and symp-
toms of heart failure. Screening for modifiable
cardiovascular risk factors, lifestyle modification and,
where appropriate, pharmacological treatment to correct
the risk factors, are highly recommended. Regular exer-
cise is advisable for all patients, whereas vigorous physical
activity that includes intense isometric exercises should
not be encouraged in patients at high risk of CTX (high
doses, concomitant radiotherapy).
Because of the scarcity of evidence, suggestions for
medical surveillance are largely based on consensus.
The observation programme that includes two-dimen-
sional echocardiography, the most appropriate instru-
ment for the follow-up of patients, should start
6months after completion of therapy. For low-risk
patients without preexisting CVD who do not undergo
treatment with high ANT doses and who show no
changes in LVEF, GLS or troponin during treatment,
annual cardiovascular clinical evaluation is recom-
mended, as is echocardiographic assessment every
5 years. More frequent monitoring is reasonable for
survivors who are at high and moderate risk of ANT
cardiomyopathy. In the presence of signs or symptoms
suggestive of CVD, an echocardiographic examination is
indicated as soon as possible.
The clinical suspicion of heart failure and/or echocardio-
graphic evidence of changes, such as LVEF drop,
chamber dilation and valve abnormalities call for a
prompt cardiology consultation. Patients with preexisting
CVD, as well as those who showed signs of early CTX
during chemotherapy and started cardiovascular therapy
should periodically be evaluated by a cardiologist.
Periodic assessment of BNP and troponin could play a
complementary role in particular circumstances such as in
patients with borderline echocardiographic data.
Conclusion
A-CTX has been a well known problem for more than
40 years, but there are still several unresolved issues and
unanswered questions. From the patient’s point of view,
there is an urgent need for specialized care that involves
carefully integrating the knowledge of cardio-oncology
into daily practice. In order to make this possible, training© 2016 Italian Federation of Caat least one cardiologist in the management of cardiovas-
cular problems of cancer patients is recommended in all
hospitals having an oncological or haemato-oncological
Unit. Cardio-oncology is a rapidly growing area. Although
keeping up-to-date is certainly necessary, we feel that an
even more critical issue is represented by the goal for
oncologists and cardiologists to join forces and learn to
work side by side.
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